Scarica l'app Stockscreener
0.75
3.49%
-0.0271
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SCYX Giù?
Forum
Previsione
Frazionamento azionario
Scynexis Inc Borsa (SCYX) Ultime notizie
Market Moves: Is SCYNEXIS Inc backed by strong institutional buyingQuarterly Portfolio Report & AI Forecast Swing Trade Picks - baoquankhu1.vn
Invasive Fungal Infections Market to Witness Upsurge in Growth at a CAGR of 11.4% (in the US) During the Forecast Period (2025-2034) | DelveInsight - The AI Journal
FOMO Trade: Does SCYNEXIS Inc have pricing powerJuly 2025 Levels & Community Driven Trade Alerts - baoquankhu1.vn
Swing Trade: Is SCYNEXIS Inc backed by strong institutional buyingMarket Performance Summary & Weekly Consistent Profit Watchlists - baoquankhu1.vn
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting - marketscreener.com
Scynexis (SCYX) to Present Data on Advanced Antifungal Drug at K - GuruFocus
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) - The Manila Times
New antifungal SCY-247 shows potent activity against deadly drug-resistant fungi - stocktitan.net
Companies Like SCYNEXIS (NASDAQ:SCYX) Could Be Quite Risky - Sahm
Aug Macro: Can SCYNEXIS Inc expand into new marketsQuarterly Earnings Summary & Safe Entry Trade Reports - baoquankhu1.vn
JERSEY CITYFDA grants fast track and QIDP designations to SCYNEXIS drug - Investing.com Nigeria
Scynexis (SCYX) Gains FDA Designations for Antifungal Therapy SC - GuruFocus
Scynexis receives FDA qualified infectious disease product and fast track designations for SCY-247 - marketscreener.com
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 - The Manila Times
FDA fast-tracks new antifungal aimed at deadly Candida auris infections - Stock Titan
Breakout Move: Is SCYNEXIS Inc benefiting from innovation trendsMarket Sentiment Review & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Aug Volume: Is SCYNEXIS Inc stock trending bullishWeekly Trade Analysis & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
FEDERATED HERMES, INC. Acquires Additional Shares in SCYNEXIS Inc. - GuruFocus
Retail Trends: Can SCYNEXIS Inc expand into new marketsWeekly Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
RSI Check: Is SCYNEXIS Inc benefiting from innovation trendsWeekly Trend Report & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Jobs Data: Will SCYNEXIS Inc stock continue dividend increasesJuly 2025 Levels & Community Driven Trade Alerts - Bộ Nội Vụ
Published on: 2026-01-11 17:42:44 - Улправда
SCYNEXIS halts phase 3 MARIO trial, raising new questions for ibrexafungerp’s growth path - MSN
Why SCYNEXIS Inc. (135A) stock is listed among top recommendationsJobs Report & Low Risk Investment Opportunities - ulpravda.ru
Why hedge funds are buying SCYNEXIS Inc. stockWeekly Trade Summary & AI Driven Price Predictions - Улправда
Gains Report: Does SCYNEXIS Inc stock trade at a discount to peersWeekly Trade Recap & Expert Curated Trade Ideas - Bộ Nội Vụ
How SCYNEXIS Inc. stock compares to industry benchmarksOptions Play & Daily Stock Momentum Reports - Улправда
Why SCYNEXIS Inc. stock is trending among retail tradersResistance Breakout Alerts & Free Rapid Return Acceleration - bollywoodhelpline.com
Portfolio Update: How SCYNEXIS Inc stock compares to industry benchmarksJuly 2025 Highlights & Free Safe Capital Growth Stock Tips - moha.gov.vn
SCYNEXIS granted Nasdaq extension to regain bid price compliance - MSN
What analysts say about SCYNEXIS Inc 135A stockFundamental Strength Indicators & Build Wealth With Expert Timing Advice - earlytimes.in
Scynexis receives 180-day extension from Nasdaq to meet listing requirements - Investing.com
Scynexis granted 180-day extension by Nasdaq to regain compliance with minimum bid price requirement - marketscreener.com
SCYNEXIS, Inc. Receives 180-Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Quiver Quantitative
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - The Manila Times
Earnings Report: Why SCYNEXIS Inc. stock is trending among retail tradersAnalyst Downgrade & Long Hold Capital Preservation Plans - Улправда
SCYNEXIS Earnings Notes - Trefis
Is SCYNEXIS Inc. stock trading at a premium valuationEarnings Risk Summary & Reliable Volume Spike Alerts - Улправда
Shorts Report: How SCYNEXIS Inc. (135A) stock compares with tech leadersEarnings Summary Report & Safe Entry Momentum Stock Tips - moha.gov.vn
SCYNEXIS Halts Phase 3 MARIO Trial, Raising New Questions for Ibrexafungerp’s Growth Path - TipRanks
Will SCYNEXIS Inc. stock deliver better than expected guidance2025 Key Lessons & Advanced Swing Trade Entry Plans - DonanımHaber
Can SCYNEXIS Inc. stock continue upward trendEarnings Summary Report & Long-Term Growth Stock Strategies - Улправда
How SCYNEXIS Inc. (135A) stock compares with tech leadersJuly 2025 Momentum & Verified Stock Trade Ideas - Bölüm Sonu Canavarı
Why SCYNEXIS Inc. stock is a must watch in 2025Market Trend Review & Fast Momentum Stock Entry Tips - Улправда
Nasdaq Moves: Why SCYNEXIS Inc. stock is a must watch in 2025Weekly Stock Recap & AI Powered Market Trend Analysis - Улправда
Is SCYNEXIS Inc. stock a contrarian buy2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - ulpravda.ru
What insider purchases suggest about SCYNEXIS Inc. (135A) stockJuly 2025 Macro Moves & AI Enhanced Trading Alerts - ulpravda.ru
Revenue per share of SCYNEXIS, Inc. – BER:135A - TradingView — Track All Markets
SCYNEXIS (NASDAQ:SCYX) versus NewAmsterdam Pharma (NASDAQ:NAMS) Head to Head Analysis - Defense World
1.19%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):